In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene (mRNA-4157), show an impressive 49% reduction in the risk of disease ...

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...

Accelerated by the COVID-19 pandemic, research is now exploring vaccines capable not only of preventing infections, but also ...

In recent years, messenger RNA (mRNA) vaccines have shown significant success in preventing viral and bacterial infections, ...

Moderna MRNA announced that it submitted regulatory filings seeking approval for its seasonal influenza vaccine mRNA-1010 across the United States, European Union, Canada and Australia. These filings ...

Add Yahoo as a preferred source to see more of our stories on Google. The U.S. government invests in vaccine development, in part, to protect soldiers from dangerous pathogens in various parts of the ...

The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...

Moderna ( MRNA) CEO Stéphane Bancel said on Thursday that his company will not fund further late-stage development of vaccines as the U.S. government pushes back against immunizations.

The U.S. Department of Health and Human Services (HHS) has canceled almost $500 million in funding for mRNA vaccine projects, alleging worries about safety and efficacy. They are winding down nearly ...